eligibility_summary
Eligibility: Multiple myeloma with ≥1 dose of teclistamab (REALiTEC: first dose ≤12/31/22 [C1], 1/1/23–12/31/24 [C2], or 1/1/25–12/31/25 [C3]) or talquetamab (REALiTAL: first dose ≤12/31/23). Consent or waiver required. Dual-exposed patients may join both cohorts. Exclusions: receipt of teclistamab (REALiTEC) or talquetamab (REALiTAL) in an interventional trial, teclistamab via Janssen pre-approval access excludes from REALiTEC C2–C3.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational, retrospective real‑world study in RRMM assessing outcomes with two T‑cell redirectors used outside trials: 1) Teclistamab (TECVAYLI) – an off‑the‑shelf, full‑length bispecific antibody (T‑cell engager). Mechanism: binds BCMA (on malignant plasma cells) and CD3 (on T cells), activating and redirecting cytotoxic T cells to kill myeloma cells. Targets: BCMA pathway on plasma cells and T‑cell activation via CD3. 2) Talquetamab (TALVEY) – a bispecific T‑cell–redirecting antibody. Mechanism: binds GPRC5D (on myeloma/plasma cells) and CD3 on T cells, inducing T‑cell–mediated cytotoxicity. Targets: GPRC5D pathway on plasma cells and T‑cell CD3 signaling. No treatments are given in the study, medical records from time‑defined cohorts are analyzed.